Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LMP744
- Development stage
- Phase 2
- Lead developer
- Gibson Oncology
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Administration
- Intravenous
01
Overview
LMP744 is a small molecule topoisomerase I inhibitor of the indenoisoquinoline class developed for the treatment of cancer. It binds to and stabilizes cleaved DNA-topoisomerase I complexes, preventing DNA re-ligation and repair, which leads to stable, irreversible DNA strand breaks, cell cycle arrest, and apoptosis[1][2]. LMP744 has demonstrated potent activity against both topoisomerase I (TOPO 1) and the cMyc oncogene[5]. The drug is notable for its ability to cross the blood-brain barrier at concentrations significantly higher than those required to kill cancer cells and sustain these levels for over 24 hours per dose[5][8]. It has received orphan drug designation from the FDA for glioma/glioblastoma treatment. Clinical studies have evaluated its safety and efficacy in patients with advanced solid tumors or lymphoma who have progressed after other treatments[4][7].
- Other names
- Topoisomerase-1 Inhibitor LMP744Topoisomerase1 Inhibitor LMP744Topoisomerase 1 Inhibitor LMP744indenoisoquinoline LMP744
02
Targets
TOP1 (DNA Topoisomerase I)telomeric G4 (Telomeric DNA G-quadruplex)MYC (MYC proto-oncogene protein)
Beyond the preview
Go deeper on LMP744.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LMP744.